[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yonsei University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":619},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,178,0,25,[9,41,67,91,115,145,171,194,215,241,264,287,311,335,362,396,417,437,465,487,510,538,556,582,603],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100477184","aspirin-vs-clopidogrel-after-tavr-100477184",false,"NCT05493657","Aspirin vs Clopidogrel After TAVR","Aspirin Versus Clopidogrel for Leaflet Thrombosis Prevention in Patients Undergoing Transcatheter Aortic Valve Replacement: ACLO-TAVR Trial","Inclusion Criteria:\n\n1. Patients \\>19 years old\n2. Patients who underwent TAVR symptomatic severe AS\n3. Provision of informed consent\n\nExclusion Criteria:\n\n1. Patients requiring dual antiplatelet therapy longer than 4 weeks\n2. Any conditions requiring specific antiplatelet therapy aspirin or clopidogrel\n3. History of stroke or transient ischemic attack (TIA) within 6 months\n4. Planned major surgery\n5. Cardiogenic shock or hemodynamic instability\n6. Chronic kidney disease stage 4 or 5 (eGFR \\\u003C30mL\u002Fmin)\n7. Valve-in-valve TAVR procedure\n8. Hypersensitivity or contraindication to aspirin or clopidogrel\n9. Indication for anticoagulation therapy","ALL","19 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"NA","Currently, the optimal antithrombotic therapy after transcatheter aortic valve replacement (TAVR) remains still unknown., The purpose of the study is to compare aspirin versus clopidogrel monoantiplatelet therapy for preventive effect on leaflet thrombosis in patients undergoing TAVR for severe aortic stenosis. This study is designed as a prospective, multicenter, open label, randomized controlled study. Eligible patients will be randomized to aspirin or clopidogrel monotherapy after TAVR. Patients will have dual antiplatelet therapy of aspirin 100 mg and clopidogrel 75 mg for 4 weeks after TAVR and then subsequent monoantiplatelet therapy of either aspirin 100 mg or clopidogrel 75 mg according to the randomization. Leaflet thrombosis will be assessed with cardiac computed tomography (CT) and transthoracic echocardiography at 3 months after TAVR. Patients will be clinically followed for 6 months. The primary endpoint is the Incidence of leaflet thrombosis on cardiac CT at 3 months.",[27],"Severe Aortic Stenosis","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":32},"2023-02-02",{"date":36,"type":21},"2027-07-21",{"name":38,"class":39},"Yonsei University","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100633239","moderate-intensity-statin-plus-ezetimibe-in-ckd-and-ascvd-100633239","NCT07524101","Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD","Utilizing Lipid-lowering Therapy With Moderate-intensity Statin Plus Ezetimibe in Chronic Kidney Disease Patients With Concomitant Atherosclerotic Cardiovascular Disease: ULTRA-CKD Trial","Inclusion Criteria:\n\n1. Age 19-85 years.\n2. Chronic kidney disease stage III, IV, or V (CKD-EPI eGFR \\\u003C60 \u002F \\\u003C30 \u002F \\\u003C15 mL\u002Fmin\u002F1.73 m² or on dialysis).\n3. Established ASCVD, meeting at least one of the following:\n\n   * Prior acute coronary syndrome (myocardial infarction or unstable angina).\n   * Stable angina confirmed by imaging studies.\n   * History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting).\n   * Peripheral artery disease.\n   * Ischemic stroke or transient ischemic attack.\n\nExclusion Criteria:\n\n1. Baseline LDL cholesterol \\\u003C55 mg\u002FdL in the absence of statin therapy.\n2. Acute liver disease or persistently unexplained serum AST\u002FALT ≥2 × the upper limit of normal.\n3. Allergy or hypersensitivity to statins.\n4. Life expectancy \\\u003C1 year.\n5. Expected inability to complete at least 1 year of follow-up.\n6. Inability to read or understand the informed consent form.","85 Years",{"count":50,"type":21},1952,[24],"The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD).\n\nPatients with CKD are at very high risk for ASCVD. In this population, it is important to establish a lipid-lowering strategy that optimizes cardiovascular outcomes while ensuring long-term safety. While high-intensity statins are generally considered as initial treatment option for secondary prevention, the optimal strategy for CKD patients remains to be clinicaly defined. This study aims to evaluate whether the combination of moderate-intensity statin and ezetimibe is non-inferior to high-intensity statin monotherapy in terms of 3-year composite of major adverse cardiovascular events.",[54,55,56,57,58],"Renal Insufficiency","Atherosclerosis","Dyslipidemia","Hypercholesterolemia","Cardiovascular Diseases","2026-06-11",{"date":61,"type":32},"2026-06-16",{"date":63,"type":32},"2026-05-28",{"date":65,"type":21},"2031-01-22",{"name":38,"class":39},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100643392","phase-2-lurbinectedin-plus-paclitaxel-versus-paclitaxel-in-patients-with-previously-treated-small-cell-lung-cancer-100643392","NCT07640932","Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer","Lurbinectedin in Combination With Paclitaxel Versus Paclitaxel for Patients With Previously Treated Small Cell Lung Cancer: Randomized, Phase II, Open-label, Multi-center, Prospective Trial(LUPINE)","LUPINE","Inclusion Criteria:\n\n1. Age ≥ 19 years.\n2. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).\n3. Patients who have experienced disease progression following at least one prior platinum-based systemic therapy for extensive-stage small cell lung cancer, including all of the following conditions:\n\n   * Patients who failed treatment within 6 months after curative-intent chemotherapy are considered as having failed first-line therapy.\n   * For platinum-sensitive patients, participation in the third-line cohort is allowed after re-treatment with a platinum-based regimen as second-line therapy (limited-stage).\n   * For platinum-resistant patients, participation in the second-line cohort is allowed (limited-stage).\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n5. At least one measurable target lesion according to RECIST v1.1 criteria.\n6. Predicted life expectancy of at least 12 weeks (3 months).\n7. Adequate hematologic, renal, metabolic, and hepatic function within 14 days prior to enrollment, defined as:\n\n   Absolute neutrophil count (ANC) ≥ 1,500\u002FμL Platelet count ≥ 100,000\u002FμL Hemoglobin (Hb) ≥ 9.0 g\u002FdL Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or calculated creatinine clearance (cCr) ≥ 60 mL\u002Fmin Total bilirubin ≤ 1.0 × ULN AST and ALT ≤ 3.0 × ULN (regardless of liver metastasis) PT and aPTT ≤ 1.5 × ULN\n8. Willingness to provide unstained slides (minimum 5, ideally 15) from archived or freshly biopsied tissue for exploratory analyses.\n9. Female participants of childbearing potential must have a negative pregnancy test (urine) at screening. If the urine test is positive or inconclusive, a negative serum pregnancy test is required.\n\n   Female participants of childbearing potential must agree to use effective contraception during the study.\n10. Male participants of reproductive potential must agree to use effective contraception during the study (see appendix for acceptable methods).\n11. Voluntary written informed consent to participate in this clinical trial.\n\nExclusion Criteria:\n\n1. Patients who have not received prior systemic therapy for small cell lung cancer (SCLC).\n2. Patients previously treated with Lurbinectedin or Paclitaxel.\n3. Patients with limited-stage small cell lung cancer (LS-SCLC).\n4. Patients with symptomatic or clinically significant brain metastases (patients with asymptomatic or stable brain metastases may be eligible; any treatment for brain metastases must have been completed at least 1 week prior to the first dose of study drug).\n5. Concomitant use of medications that may prolong the QTc interval, potent immunosuppressive agents, or drugs that may cause interstitial lung disease (ILD) is prohibited during the treatment period. If co-administration is unavoidable, prior discussion with the coordinating center is required.\n6. Patients with active primary immunodeficiency (e.g., HIV infection), active hepatitis B, or active hepatitis C:\n\n   * HBsAg-positive patients may be eligible if HBV DNA is negative or appropriate antiviral therapy is being administered.\n   * HCV antibody-positive patients may be eligible if HCV RNA is negative or the patient has been cured after treatment.\n7. Patients with active interstitial lung disease (ILD) or a history of non-infectious pneumonitis requiring steroid therapy, including immune-therapy- or chemotherapy-related ILD or Grade ≥3 pulmonary complications. (Patients with previously resolved infectious pneumonia without current clinical significance may be eligible.)\n8. Pregnant or breastfeeding women.\n9. Patients with clinically significant cardiovascular disease within the past 12 months (e.g., congestive heart failure, symptomatic coronary artery disease, arrhythmias, myocardial infarction).\n10. Patients whose toxicities from prior anticancer therapy have not recovered to baseline or ≤ Grade 2.\n11. Patients who received any prior anticancer therapy within 14 days or localized radiotherapy within 7 days before the first dose of the study drug.\n12. Patients with a known hypersensitivity to the study drugs.\n13. Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study.","20 Years",{"count":77,"type":21},69,[79],"PHASE2","This clinical trial is designed to compare and evaluate the efficacy and safety of the combination therapy of Lurbinectedin plus Paclitaxel (Combination Arm) versus Paclitaxel monotherapy (Monotherapy Arm) in patients with extensive-stage small-cell lung cancer whose disease has progressed after first-line chemotherapy.",[82],"Carcinoma, Small Cell Lung","NOT_YET_RECRUITING","2026-06-05",{"date":59,"type":32},{"date":87,"type":21},"2026-06",{"date":89,"type":21},"2029-02",{"name":38,"class":39},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":40},"100641018","the-purpose-of-this-clinical-trial-is-to-evaluate-the-accuracy-of-blood-pressure-measurement-of-hicardi-m350-compared-to-blood-pressure-measured-by-auscultatory-sphygmomanometer-in-adult-volunteers-including-those-meeting-blood-pressure-distribution-requirements-in-accordance-with-iso-81060-22018-100641018","NCT07622498","The Purpose of This Clinical Trial is to Evaluate the Accuracy of Blood Pressure Measurement of HiCardi M350 Compared to Blood Pressure Measured by Auscultatory Sphygmomanometer in Adult Volunteers (Including Those Meeting Blood Pressure Distribution Requirements) in Accordance With ISO 81060-2:2018","A Prospective, Single-center, Single-arm, Pivotal Clinical Trial to Evaluate the Accuracy of Blood Pressure Measurements From the HiCardi M350(Patient Monitor) in Comparison With Those Measured Using an Auscultatory Sphygmomanometer","Inclusion Criteria:\n\n1. Adults aged 19 years or older.\n2. Individuals who visit Severance Hospital and voluntarily provide written informed consent after receiving and understanding sufficient explanation of the study.\n3. Individuals with hypertension-range blood pressure may be included to meet the blood pressure distribution requirements. Participants receiving antihypertensive medication may be included only if the type and dose of medication have remained stable for at least 4 weeks before screening. Individuals with dose changes, medication additions, or medication discontinuation within 4 weeks before screening will be excluded.\n\nExclusion Criteria:\n\n1. Individuals in whom Korotkoff phase V cannot be clearly identified during auscultatory blood pressure measurement.\n2. Individuals for whom blood pressure measurement is difficult or expected to be difficult.\n3. Individuals with bilateral arm circumference greater than 42 cm.\n4. Pregnant women.\n5. Individuals currently participating in another clinical trial or who have participated in another clinical trial within 30 days before the screening date.\n6. Individuals judged by the investigator to be inappropriate for participation in the clinical trial.",true,{"count":100,"type":21},100,[24],"This prospective, single-center, single-arm pivotal clinical trial is designed to evaluate the accuracy of blood pressure measurements obtained using the HiCardi M350 patient monitor compared with measurements obtained using an auscultatory sphygmomanometer.\n\nThe study will enroll adult volunteers aged 19 years or older, including participants needed to satisfy the blood pressure distribution requirements of ISO 81060-2:2018. The planned enrollment is 100 participants, considering the ISO 81060-2:2018 minimum requirement of 85 participants and an estimated dropout rate of approximately 15%. The study is also designed to obtain at least 255 valid paired blood pressure values.\n\nAfter written informed consent, participants will undergo screening assessments, including demographics, vital signs, medical and surgical history, prior and concomitant medications, pregnancy testing for women of childbearing potential, bilateral arm circumference measurement, eligibility assessment, and adverse event assessment. On the blood pressure test day, eligibility will be reconfirmed, an enrollment number will be assigned, HiCardi M350 calibration will be performed, and blood pressure measurements will be obtained using both HiCardi M350 and the reference auscultatory method.\n\nThe primary effectiveness endpoint is the difference between systolic and diastolic blood pressure values measured by HiCardi M350 and the reference sphygmomanometer under resting conditions. Accuracy will be evaluated according to ISO 81060-2:2018 using Criteria 1 and Criteria 2. Safety will be evaluated based on adverse events, adverse device effects, serious adverse events, serious adverse device effects, unanticipated adverse device effects, and device deficiencies.",[104],"No Restriction on Disease",[106,107],"HiCardi M350","Blood Pressure","2026-06-01",{"date":110,"type":32},"2026-06-03",{"date":108,"type":32},{"date":113,"type":21},"2026-08-31",{"name":38,"class":39},{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":131,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":40},"100640379","in-hospital-wearable-based-monitoring-versus-standard-care-in-cardiovascular-disease-inspire-100640379","NCT07622485","In-Hospital Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease (INSPIRE)","In-Hospital Efficacy and Safety of Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease: A Stepped-Wedge Cluster Randomized Controlled Trial (INSPIRE Trial)","Inclusion Criteria:\n\nAdults aged 20 years or older\n\n* Hospitalized for cardiovascular disease, with at least one of: acute coronary syndrome; chronic coronary syndrome; acute heart failure (NYHA class III-IV or acute decompensated heart failure); arrhythmia (atrial fibrillation, ventricular tachycardia, complete AV block, or other clinically significant arrhythmia); peripheral arterial or aortic disease; post-cardiovascular-procedure observation (PCI, CABG, valve surgery, or electrophysiology study); or thromboembolic disease\n* Able to provide written informed consent\n* Able to wear the wearable monitoring device\n\nExclusion Criteria:\n\n* Hemodynamically unstable shock (sustained systolic blood pressure \\\u003C 90 mmHg requiring vasopressors; cardiogenic shock; septic shock)\n* Planned or current intensive care unit admission\n* Within 24 hours after cardiopulmonary resuscitation\n* Physical condition precluding device wearing (bilateral upper-limb amputation; severe skin lesion, burn, or open wound at the device site; known allergy to device materials)\n* Severe cognitive impairment or delirium precluding informed consent Extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP) in use\n* Continuous renal replacement therapy (CRRT) in use (patients on CRRT may participate if hemodynamically stable and device wearing is technically feasible)\n* Unable to communicate in Korean for study explanation and the consent process\n* Previously enrolled in this study (re-admitted patients are not re-enrolled; each participant is enrolled only at the first admission)\n* Considered inappropriate for participation by the investigator",{"count":123,"type":21},1500,[24],"Patients hospitalized with cardiovascular disease require timely detection of clinical deterioration to prevent adverse outcomes. Standard inpatient care relies on intermittent nursing vital-sign measurements performed every 4 to 8 hours, which can miss hemodynamic or arrhythmic events occurring between measurements. This trial evaluates whether digital wearable-based monitoring - wireless continuous measurement of vital signs and electrocardiography with a real-time alerting system - reduces major adverse cardiovascular events (MACE) compared with standard intermittent monitoring in patients hospitalized for cardiovascular disease. The trial uses a stepped-wedge cluster-randomized design in which four inpatient ward zones (clusters) are sequentially transitioned from standard care to wearable monitoring over five periods.",[58,127,128,129,130],"Acute Coronary Syndrome","Heart Failure","Cardiac Arrhythmia","Peripheral Arterial Disease",[132,133,134,135,136,137,138],"wearable device","continuous monitoring","remote monitoring","stepped-wedge cluster trial","major adverse cardiovascular events","digital health","inpatient monitoring",{"date":110,"type":32},{"date":141,"type":21},"2026-07-01",{"date":143,"type":21},"2029-12-31",{"name":38,"class":39},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100639110","phase-2-everolimus-and-lenvatinib-versus-everolimus-for-bone-sarcoma-100639110","NCT07619950","EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma","EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma Progressing After Standard Treatmen : a Randomized, Phase 2, Multi-center Trial [EVERLAST]","Inclusion Criteria:\n\n1. Histologically confirmed advanced Osteosarcoma, Ewing sarcoma, Chondrosarcoma with 1-2 prior chemotherapy\n\n   : neoadjuvnat or adjuvant chemotherapy is counted as one regimen\n2. Age ≥19 years, \\\u003C80 years\n3. ECOG performance status of 0-1\n4. Has at least 1 measurable lesion (as defined by Response Evaluation Criteria in Solid Tumors Version 1.1).\n5. Has adequate organ function defined by the following criteria:\n\n   * Hb ≥ 9.0 g\u002FdL\n   * Absolute neutrophil count (ANC) ≥ 1000 \u002FµL\n   * Platelet ≥ 75,000\u002F µL\n   * Serum Creatinine: ≥ 50 mL\u002Fmin\n   * Total Bilirubin: ≤ 1.5 × UNL (upper normal limit)\n   * AST(SGOT)): ≤ 3.0 × UNL or ≤ 5.0 × UNL (in patients with liver metastasis)\n   * ALT(SGPT): ≤ 3.0 × UNL or ≤ 5.0 × UNL (in patients with liver metastasis)\n6. Female patient of childbearing potential has a negative serum or urine pregnancy test for β-hCG\n7. Able to provide written informed consent and comply with the protocol requirements\n\n   Exclusion Criteria:\n   * Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment within 2 weeks prior to entering the study. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable\n\n     * Any previous treatment to lenvatinib or mTOR inhibitor\n\n       * Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria\n\n         * Major surgical procedure (as defined by the Investigator) within 14 days prior to the first dose of IP ⑤Active or prior documented autoimmune or inflammatory disorders\n\n           -including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\n           * History of the following conditions within the past 6 months.\n\n             * coronary angioplasty or stent placement, myocardial infarction, unstable angina, coronary artery bypass grafting, peripheral arterial disease (Grade III) or congestive heart failure (Grade IV) according to the New York Heart Association classification, thromboembolism (patients on stable anticoagulation for ≥6 weeks are eligible), hemoptysis, intracranial hemorrhage, or clinically significant gastrointestinal bleeding ⑦Has an active infection requiring parenteral treatment\n\n               * History of another primary malignancy.\n\n   However, enrollment is permitted in the following cases:\n   * Basal cell or squamous cell carcinoma of the skin after curative resection\n   * Cervical carcinoma in situ after at least 1 year following successful treatment\n   * Patients who have been disease-free for at least 3 years after completion of treatment\n\n     ⑨Known or active CNS metastasis and\u002For carcinomatous meningitis\n   * Participants with previously treated brain metastases are eligible if radiologically stable.\n\n     * female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to emply effective birth control from screening to 90 days after the last dose","15 Years","79 Years",{"count":155,"type":21},94,[79],"Those studies demonstrate strong rationale to combine a multikinase inhibitor targeting VEGFR, PDGFR with mTOR inhibitor. Moreover, another multi-targeted TKI, lenvatinib monotherapy showed promising activity in osteosarcoma. Therefore, clinical trial with Lenvatinib in combined with everolimus is ongoing for solid tumors (NCT03245151). Considering lenvatinib and everolimus (18 mg\u002Fday and 5 mg\u002Fday) already approved as standard treatment for renal cell carcinoma based on the powerful ORR, PFS, and OS14, these noteworthy findings advance the treatment paradigm for bone sarcoma patients.\n\nBecause all those trials for sarcoma were done in the absence of a control group, based on such clinical studies, a confirmatory trial comparing mTOR inhibitor and a multi-targeted tyrosine kinase inhibitor (multi-TKI) combination versus monotherapy is essential. Therefore, we planned to conduct the randomized phase II trial of everolimus in combination with lenvatinib for advanced\u002Fmetastatic bone sarcomas. In addition, we will explore predictive biomarkers by repeated biopsies and blood samplings during the treatment.",[159],"Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical Site",[161,162,163],"Everolimus","Lenvatinib","Bone Sarcoma","2026-05-26",{"date":166,"type":32},"2026-06-02",{"date":141,"type":21},{"date":169,"type":21},"2028-11-30",{"name":38,"class":39},{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},"100639793","comparison-of-operator-radiation-exposure-during-percutaneous-coronary-intervention-between-left-distal-and-right-conventional-radial-access-100639793","NCT07579169","Comparison of Operator Radiation Exposure During Percutaneous Coronary Intervention Between Left Distal and Right Conventional Radial Access","Comparison of Operator Radiation Exposure During Percutaneous Coronary Intervention Between Left Distal and Right Conventional Radial Access: A Multicenter, Randomized Trial","DOSE-PCI","Inclusion Criteria:\n\n1. Patients aged 19 years or older\n2. Patients scheduled for PCI\n\nExclusion Criteria:\n\n1. Non-palpable left distal radial artery pulse\n2. Non-palpable right radial artery pulse\n3. Presence of arteriovenous fistula\n4. Need for femoral access as determined by the investigator\n5. Refusal to provide informed consent\n6. Pregnant or breastfeeding women",{"count":180,"type":21},748,[24],"This study aims to compare the operator's radiation exposure between left distal radial access (LDRA) and right transradial access (RTRA) in patients undergoing percutaneous coronary intervention (PCI).",[184],"Radiation Exposure",[177],"2026-05-21",{"date":188,"type":32},"2026-05-27",{"date":108,"type":21},{"date":191,"type":21},"2029-04-21",{"name":38,"class":39},4,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100631024","phase-1-ultra-hypofractionated-carbon-ion-therapy-for-prostate-cancer-100631024","NCT07495293","Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer","Carbon-ion Therapy With Ultra-hypofractionated RadiothErapy for Localized Prostate Cancer (CURE-PC-1): Phase I Clinical Trial","Inclusion Criteria:\n\n1. Male patients aged 19 years or older who are able to provide written informed consent\n2. Histologically confirmed prostatic adenocarcinoma within 6 months prior to the first treatment (either carbon ion radiotherapy or androgen deprivation therapy, whichever comes first)\n3. Documented pre-biopsy serum prostate-specific antigen (PSA) level available\n4. Classified as one of the following risk groups based on NCCN Guidelines Version 5.2026:\n\n   * Low risk: PSA ≤10 ng\u002FmL AND Gleason score 6 (Grade Group 1) AND cT1-T2a\n   * Intermediate risk: PSA 10-20 ng\u002FmL OR Gleason score 7 (Grade Group 2-3) OR cT2b-T2c, without any high-risk features\n5. No evidence of distant metastasis or regional lymph node metastasis\n6. Adequate general condition for prostate cancer treatment as determined by ECOG Performance Status 0 or 1\n7. Multiparametric prostate MRI performed prior to biopsy\n\nExclusion Criteria:\n\n1. Prior history of pelvic radiotherapy or prostate surgery\n2. History of malignancy other than prostate cancer, except for the following: cervical carcinoma in situ, completely resected non-melanoma skin cancer, or any cancer with disease-free status maintained for 5 or more years after treatment\n3. Patients deemed inappropriate for carbon ion radiotherapy due to active infection, bleeding disorders, or severe cardiac, hepatic, or renal dysfunction, or patients who have undergone major surgery or experienced a major cardiovascular event (e.g., myocardial infarction, cerebral infarction, or cerebral hemorrhage) within the past 6 months\n4. Patients with evidence of prostatitis or urinary tract infection on screening urinalysis and urine culture (However, enrollment is permitted if the condition improves on follow-up evaluation prior to carbon ion radiotherapy.)\n5. Patients with psychiatric disorders or cognitive impairment considered unable to comply with the treatment plan\n6. Patients currently participating in another investigational drug or medical device study concurrently with this study\n7. Patients for whom carbon ion radiotherapy is physically difficult due to artificial hip prostheses or other metallic implants\n8. Patients who underwent multiparametric prostate MRI after biopsy\n9. Patients with a history of surgical treatment for benign prostatic hyperplasia, such as transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HoLEP)",{"count":202,"type":21},20,[204],"PHASE1","This is a single-arm, exploratory phase I clinical trial evaluating the safety and efficacy of ultra-hypofractionated carbon ion radiotherapy (CIRT) in 6 fractions compared to the conventional 12-fraction regimen in patients with low- and intermediate-risk localized prostate cancer. A total of 20 patients will be enrolled sequentially and treated with CIRT at 7 GyE per fraction, delivered twice weekly on alternating days, for a total of 6 fractions (total prescribed dose: 42 GyE). Androgen deprivation therapy for 6 months will be administered concurrently in patients classified as unfavorable intermediate-risk. The primary endpoint is the incidence of acute treatment-related toxicity of Grade 3 or higher per CTCAE v5.0 occurring within 90 days after completion of CIRT. Secondary endpoints include the incidence of late toxicity, biochemical relapse-free survival (bRFS), and quality of life assessed by EPIC-26 and IPSS questionnaires. Patients will undergo scheduled follow-up visits for 2 years after treatment completion, followed by long-term follow-up through electronic medical record review up to 5 years.",[207],"Prostate Cancer","2026-05-20",{"date":210,"type":32},"2026-05-22",{"date":108,"type":21},{"date":213,"type":21},"2031-03-08",{"name":38,"class":39},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":98,"sex":17,"minAge":222,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":226,"conditions":227,"keywords":230,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":40},"100621228","exercise-echocardiography-registry-for-ischemic-and-non-ischemic-heart-disease-100621228","NCT07367893","Exercise Echocardiography Registry for Ischemic and Non-Ischemic Heart Disease","Exercise-Echo","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Patients referred for clinically indicated exercise echocardiography as part of routine clinical care\n* Patients evaluated for suspected or known ischemic heart disease, or non-ischemic heart disease, including but not limited to: Cardiomyopathy, Heart failure, Valvular heart disease, Structural heart disease\n* Ability to perform exercise-based stress testing using treadmill or bicycle protocols\n* Availability of baseline clinical data and interpretable echocardiographic images obtained during rest and exercise\n* Provision of informed consent, or eligibility for consent waiver in accordance with institutional review board approval\n\nExclusion Criteria:\n\n* Inability to perform exercise testing due to non-cardiac limitations, such as severe orthopedic, neurologic, or pulmonary conditions\n* Poor echocardiographic image quality that does not allow meaningful interpretation of exercise-induced changes\n* Any condition deemed by the treating physician to make participation inappropriate or unsafe, even within an observational framework","18 Years",{"count":224,"type":21},10000,"OBSERVATIONAL","Exercise echocardiography is a widely used non-invasive test that evaluates cardiac structure and function during physical stress. It provides important information on myocardial ischemia, cardiac performance, hemodynamic responses, and exercise capacity in patients with a broad range of heart diseases. However, real-world prospective data integrating exercise echocardiographic findings across both ischemic and non-ischemic heart disease remain limited.\n\nThis prospective observational registry aims to systematically collect clinical, exercise, and echocardiographic data from patients undergoing clinically indicated exercise echocardiography. The registry includes patients with suspected or established ischemic heart disease as well as those with non-ischemic cardiac conditions, such as cardiomyopathies, heart failure, valvular heart disease, and exercise-related symptoms.\n\nThe collected data will be used to evaluate exercise-induced changes in cardiac structure and function, identify phenotypes associated with adverse clinical outcomes, and improve risk stratification in routine clinical practice. The registry is observational in nature and does not alter standard clinical care.",[228,229],"Ischemic Heart Diease","Non-ischemic Heart Disease",[231,232,233,234],"Exercise echocardiography","Ischemic heart disease","non-ischemic heart disease","clinical outcome",{"date":210,"type":32},{"date":237,"type":32},"2026-04-01",{"date":239,"type":21},"2035-12-31",{"name":38,"class":39},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":40},"100611316","clinical-effectiveness-of-a-motivational-interviewing-based-conversational-mobile-application-for-high-risk-drinkers-100611316","NCT07238998","Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers","Evaluating the Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers","Inclusion Criteria:\n\n1. Individuals aged 19 to 59 years who are capable of providing valid written informed consent.\n2. Individuals who meet the definition of high-risk drinking (AUDIT score ≥ 8).3.- Individuals who express a desire to reduce their alcohol consumption.\n3. Individuals who own and use an Android smartphone (version 8 or higher).\n4. Individuals who have no difficulty using mobile applications.\n5. Individuals who are able to communicate adequately with the research team.\n6. Individuals who fully understand the study procedures and voluntarily agree to participate.\n\nExclusion Criteria:\n\n1. Individuals who are unable to read or understand the consent form (e.g., illiterate individuals, non-Korean speakers).\n2. Individuals with impaired decision-making capacity.\n3. Pregnant individuals or those planning to become pregnant during the study period.\n4. Individuals who are currently participating in another clinical study.\n5. Individuals who are receiving treatment or counseling for alcohol-related problems.\n6. Individuals who use two or more mobile phones.\n7. Individuals who are expected to change their mobile phone or SIM card, or who plan to travel 8. abroad during the intervention period.\n8. Any individual deemed inappropriate for study participation at the discretion of the investigator.","59 Years",{"count":250,"type":21},220,[24],"This study aims to evaluate and compare the degree of alcohol reduction between high-risk drinkers who use a motivational interviewing-based conversational agent (chatbot) application for four weeks and those in the control group who do not use the application, in order to verify its clinical effectiveness.",[254,255],"Alcohol Drinking","High-Risk Drinking Patterns","2026-05-11",{"date":258,"type":32},"2026-05-13",{"date":260,"type":32},"2025-12-19",{"date":262,"type":21},"2027-04",{"name":38,"class":39},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":40},"100339034","phase-1-concurrent-neoadjuvant-chemoradiotherapy-plus-durvalumab-medi4736-in-resectable-stage-iii-nsclc-100339034","NCT03694236","Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC","Inclusion Criteria:\n\nFor inclusion in the study subjects must fulfill all of the following criteria:\n\n1. Histologically confirmed NSCLC\n2. Clinical stage III (including N2 stage and potential candidate for resection)\n3. Written informed consent and any locally-required authorization (IRB) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations\n4. Age \\> 20 years at time of study entry\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n6. Adequate normal organ and marrow function as defined below:\n\n   * Haemoglobin ≥ 9.0 g\u002FdL\n   * Absolute neutrophil count (ANC) ≥ 1,500μL\n   * Platelet count ≥ 100,000μL\n   * Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). \\\u003CThis will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.\\>\\>\n   * AST (SGOT)\u002FALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤ 5x ULN\n   * Serum creatinine CL\\>40 mL\u002Fmin by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:\n\n     * Males:\n\nCreatinine CL (mL\u002Fmin) = Weight (kg) x (140 - Age) 72 x serum creatinine (mg\u002FdL)\n\n--Females: Creatinine CL (mL\u002Fmin) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg\u002FdL) 6. Life expectancy of 6 months 8. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥50 years old and no menses for 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.\n\n9\\. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nExclusion Criteria:\n\nSubjects should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Patients with metastatic lesions or clinical N3 lymph nodes\n2. Participation in another clinical study with an investigational product during the last 60 months\n3. Involvement in the planning and\u002For conduct of the study (applies to both AstraZeneca staff and\u002For staff at the study site) Previous enrollment in the present study\n4. Any previous treatment (chemotherapy, radiotherapy or surgery) to current disease - NSCLC\n5. Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab\n6. History of leptomeningeal carcinomatosis\n7. Brain metastases or spinal cord compression. Subjects with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry\n8. Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) ≤ 36months prior to the first dose of study drug\n9. Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction\n10. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\u002Fday of prednisone, or an equivalent corticosteroid\n11. Current or prior use of immunosuppressive medication within 14days (use 28 days if combining durvalumab with a novel agent) before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\u002Fday of prednisone, or an equivalent corticosteroid. The following are exceptions to this criterion:\n\n    * Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)\n    * Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n    * Steroids as premedication for hypersensitivity reactions (eg, chemotherapy, CT scan premedication)\n12. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.\n13. History of allogeneic organ transplant\n14. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n    * Subjects with vitiligo or alopecia\n    * Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement\n    * Any chronic skin condition that does not require systemic therapy\n    * Subjects without active disease in the last 5 years may be included but only after consultation with the study physician\n    * Subjects with celiac disease controlled by diet alone\n15. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent\n16. History of another primary malignancy except for Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence\n\n    * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n    * Adequately treated carcinoma in situ without evidence of disease\n    * Adequately treated thyroid cancer (except. Anaplastic thyroid cancer)\n17. History of primary immunodeficiency\n18. Active pulmonary tuberculosis (Patients with old tuberculosis can be enrolled) Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent\n19. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab\n20. 21\\. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control\n21. History of hypersensitivity to the combination or comparator agent\n22. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.\n23. Inability to comply with protocol or study procedures.",{"count":271,"type":21},39,[204,79],"Combination treatment of Durvalumab with chemoradiotherapy is ongoing for head\u002Fneck cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer (NCT02318771) and pancreatic cancer (NCT02305186).Combining Durvalumab with neoadjuvant chemoradiotherapy is a promising strategy to improve clinical outcome in stage III lung cancer. Using serial biopsied and surgically resected fresh tissue through the novel\u002Fhigh-throughput RNA sequencing technologies, we want to identify the change immune signature in tumor microenvironment of NSCLC patients after Durvalumab treatment. With hypothesis that PD-1 inhibitor as a component of neoadjuvant chemoradiotherapy followed by surgery could increase complete pathologic response rate and disease free survival, and overall survival, we suggest adding Durvalumab to neoadjuvant chemoradiation in stage II\u002FIII resectable NSCLC. And with immune marker study using FACS, whole exome sequencing, or RNAsequencing, we can find the potential predictive biomarker for anti-PD-L1 blockade. And in this study, we can get \"whole\" surgical specimen not biopsy sample after Durvalumab treatment so the analysis for immune marker, tumor microenvironment, and various tumor infiltrating immune cells and their changes will be available.",[275],"Potentially Resectable Stage II\u002FIIIa NSCLC",[277,278,279],"NSCLC","Durvalumab","medi4736",{"date":281,"type":32},"2026-05-14",{"date":283,"type":32},"2019-02-12",{"date":285,"type":21},"2027-05",{"name":38,"class":39},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":40},"100556681","phase-4-effect-of-enavogliflozin-on-recurrence-of-atrial-fibrillation-after-catheter-ablation-100556681","NCT06528262","Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation","ENavogliflozin And preVention Of Atrial Fibrillation Recurrence After Catheter Ablation for Atrial Fibrillation With Heart Failure (ENAVO-AF): Prospective, Multicenter, Randomized, Placebo-controlled Double-blind Clinical Trial","ENAVO-AF","Inclusion Criteria:\n\n1. Adults aged 19 to under 85\n2. Patients who consent to participate in the study and can be followed up during the study\n3. Patients with AF and heart failure who have undergone atrial fibrillation catheter ablation within the last three months or are scheduled to undergo the procedure\n\nExclusion Criteria:\n\n1. Under 19 or over 85 years old\n2. Patients who have participated in another clinical trial within the last three months\n3. Life expectancy of less than one year\n4. Pregnant or breastfeeding women\n5. Currently being treated with an SGLT-2 inhibitor\n6. Three or more urinary or genital infections within the last year\n7. Uncontrolled hypertension: systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 110mmHg\n8. Systolic blood pressure \\\u003C 90mmHg\n9. Acute cardiovascular event within the last 12 weeks\n10. Severe valvular disease or presence of artificial valves\n11. Renal impairment (eGFR CKD-EPI \\\u003C 60 ml\u002Fmin\u002F1.73m²)\n12. Clinically confirmed liver dysfunction\n13. Uncontrolled thyroid dysfunction\n14. Patients with active cancer (including those undergoing treatment) or history of cancer within the last five years at the time of screening; however, borderline cancers are not excluded if successfully treated and recurrence-free for 2-3 years.\n15. Continuous use of oral prednisolone at 10mg\u002Fday or equivalent, or higher doses of steroids, within the last month\n16. Patients with hypersensitivity or history of hypersensitivity to the active or inactive ingredients of this drug\n17. Patients with type 1 diabetes or diabetic ketoacidosis\n18. History of alcohol or substance abuse\n19. Women of childbearing potential who do not agree to use adequate contraception during the clinical trial period","84 Years",{"count":297,"type":21},390,[299],"PHASE4","Objective: The purpose of this study is to determine if there is a difference in the recurrence rate of atrial fibrillation (AF) between a group of patients with AF and heart failure undergoing catheter ablation who are administered the SGLT2 inhibitor, Enavogliflozin, and a control group (placebo group). This study aims to investigate whether SGLT2 inhibitors can prevent the recurrence of AF after the procedure.\n\nBackground: AF is the most common arrhythmia requiring treatment, with its prevalence increasing with age. In the US, AF affected 5.2 million people in 2010 and is projected to reach 12.1 million by 2030. In South Korea, prevalence rose from 0.73% in 2006 to 1.53% in 2015. Early-stage AF patients benefit more from rhythm control therapy than from heart rate control alone, as shown by the 2020 EAST-AFNET-4 trial, which reported a 21% reduction in adverse cardiovascular events. Catheter ablation for rhythm control significantly reduces AF recurrence compared to antiarrhythmic drugs, leading to more patients undergoing this procedure. AF and heart failure often coexist, forming a vicious cycle that exacerbates both conditions and leads to poorer outcomes. They share common risk factors like hypertension, diabetes, ischemic heart disease, and valvular disease. Heart failure increases left atrial filling pressure and alters intracellular calcium levels, raising AF risk. Further research is needed on their pathophysiological link. SGLT2 inhibitors reduce glucose reabsorption in the kidneys to control hyperglycemia in diabetics and have been shown in large studies (DAPA-HF, EMPEROR-Reduced) to significantly reduce heart failure worsening and cardiovascular mortality, regardless of diabetes status. These benefits were seen in both HFrEF and HFpEF. In the DAPA-HF trial, 55% of participants were non-diabetic, and reductions in heart failure worsening or cardiovascular death were similar between those with and without diabetes (25% vs. 27%). Adverse events, including volume depletion and renal function decline, were not significantly different between diabetic and non-diabetic patients, and no hypoglycemia or ketoacidosis occurred in non-diabetic patients. Recent studies show SGLT2 inhibitors reduce AF incidence and benefit heart failure. A sub-analysis of the DECLARE-TIMI 58 trial reported a 19% reduction in AF risk among diabetic patients with SGLT2 inhibitors. Meta-analyses by Okunrintemi and Zheng showed an 18% reduction in AF risk irrespective of diabetes status. Interest is growing in the relationship between SGLT2 inhibitors and AF recurrence post-catheter ablation. Luo et al. reported a nearly 39% reduction in AF recurrence post-ablation with dapagliflozin in diabetic patients. Kishima et al. found a 49% reduction in AF recurrence post-ablation with SGLT2 inhibitors versus DPP-IV inhibitors in a small prospective randomized study. However, most studies were retrospective, sub-analyses, or small-scale studies limited to diabetics. Prospective randomized studies involving AF patients regardless of diabetes status are urgently needed for validation.",[302],"Atrial Fibrillation","2026-05-07",{"date":305,"type":32},"2026-05-12",{"date":307,"type":32},"2025-04-03",{"date":309,"type":21},"2027-05-31",{"name":38,"class":39},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":98,"sex":17,"minAge":318,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":4},"100640410","sacb-vs-cacb-in-tka-100640410","NCT07581886","sACB vs cACB in TKA","Comparison of Single-shot vs. Continuous Adductor Canal Block Analgesic Effects With Catheter Positioning Confirmation in Total Knee Arthroplasty: a Double-blinded Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 40-80 yrs\n* Scheduled for unilateral total knee arthroplatsy\n* ASA I-III\n* BMI 18-35 kg\u002F㎡\n* Able to read and understand consent form\n\nExclusion Criteria:\n\n* Allergy to local anesthetics\n* Infection at the block site\n* History of neuropathy or peripheral nerve disease\n* Coagulation disorders or use of anticoagulants (if discontinuation is not possible)\n* Communication disorders or cognitive impairment\n* Chronic opioid use (≥30 MME\u002Fday, 3 months or more)\n* Severe chronic pain (NRS ≥7\u002F10, 3 months or more)\n* Renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Hepatic impairment (Child-Pugh C)\n* Blood coagulation disorders\n* Pregnancy","40 Years","80 Years",{"count":321,"type":21},78,[24],"This study compares the analgesic efficacy of single-dose adductor canal block (sACB) versus continuous-dose adductor canal block (cACB) for postoperative pain management in total knee replacement patients. To ensure a high level of clinical accuracy, the investigation specifically focuses on a cACB cohort where ultrasound confirmation ensures the catheter remains correctly positioned for a full 48 hours. Participants are assigned to groups using a 1:1 randomization protocol via computer-generated tables to eliminate selection bias. Clinical consistency is maintained by using identical pharmacological agents across both groups: 0.5% Heavy Bupivacaine for spinal anesthesia and 0.5% ropivacaine with 1:200,000 epinephrine for the nerve block itself. Furthermore, both groups adhere to a standardized multimodal analgesic schedule to control for external variables. In the cACB group, intravenous patient-controlled analgesia (IV PCA) serves as a designated rescue therapy should the catheter fail. The primary technical evaluation occurs 48 hours post-surgery, utilizing ultrasound to verify catheter placement and quantify pain levels. Beyond immediate recovery, the study evaluates long-term success through Patient-Reported Outcome Measures (PROMs) at a 12-week follow-up, focusing on functional restoration and the patient's overall quality of life. By isolating the variable of catheter stability, the research aims to provide a definitive comparison of whether the continuous delivery of local anesthetic offers a statistically significant clinical advantage over a single-dose administration in the context of modern orthopedic recovery protocols.",[325,326,327],"Arthroplasty","Replacement","Knee","2026-05-06",{"date":305,"type":32},{"date":331,"type":21},"2026-05-18",{"date":333,"type":21},"2028-01-31",{"name":38,"class":39},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":343,"minAge":222,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":360,"locationsCount":361},"100517924","phase-2-a-three-arm-randomized-phase-ii-study-of-dostarlimab-alone-or-with-bevacizumab-versus-nonplatinum-chemotherapy-in-recurrent-gynecological-clear-cell-carcinoma-dove-apgot-ov7-engot-ov80-study-100517924","NCT06023862","A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7\u002F ENGOT-ov80 Study)","A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07\u002F ENGOT-ov80 Study)","DOVE","Inclusion Criteria:\n\n1. Female patient is at least 18 years of age,\n2. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.\n3. Patient with histologically proven confirmed recurrent or persistent clear cell carcinoma of the ovary, endometrium, cervix, vagina, and vulva\n\n   * Local review by gynecologic pathologist required\n   * ≥50% clear cell histology in case of mixed carcinoma\n   * WT-1 neg (Only in case of ovarian cancer) Note: In the case of including non-ovarian clear cell carcinoma with more than 20 cases, the decision is made through discussion with the SPONSOR.\n4. Patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n5. Disease progression within 12 months of completing platinum-based chemotherapy\n6. 1-5 prior lines of therapies\n7. Patient with measurable disease according RECIST 1.1 criteria\n8. Availability of Tumor tissue for translational research . - A formalin-fixed paraffin-embedded (FFPE) tumor block(preferred) or at least 20 slides (unstained, freshly cut, serial sections) must be submitted.\n9. Patients who consent to fresh tumor biopsies\n\n   * Confirmed with at least one lesion with location accessible to safely biopsy per the clinical judgement of the investigator\n   * Note: If mandatory biopsies cannot be performed as per investigator's clinical judgement, discussion and agreement between investigator and Sponsor are required.\n10. Patient has adequate organ function, defined as follows:\n\n    1. Absolute neutrophil count ≥ 1,500 cells\u002FμL\n    2. Platelets ≥ 100,000 cells\u002FμL\n    3. Hemoglobin ≥ 9 g\u002FdL or ≥ 5.6 mmol\u002FL\n    4. Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL\u002Fmin using the Cockcroft-Gault equation for patients with creatinine levels \\> 1.5× institutional ULN\n    5. Total bilirubin ≤ 1.5× ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) or direct bilirubin ≤ 1× ULN\n    6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN\n    7. International normalized ratio or prothrombin time (PT) ≤1.5× ULN and activated partial thromboplastin time ≤1.5× ULN.Participants taking anticoagulants may be included on a stable dose with a therapeutic INR \\\u003C3.5. .\n11. Patient must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of non-childbearing potential. If a negative result cannot be confirmed by a urine test, a serum pregnancy test is required. Non-childbearing potential is defined as follows:\n\n    1. Patient is ≥ 45 years of age and has not had menses for \\> 1 year.\n    2. A follicle-stimulating hormone value in the postmenopausal range upon screening evaluation if amenorrhoeic for \\\u003C 2 years without a hysterectomy and oophorectomy.\n    3. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation:\n\n       * Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.\n       * Tubal ligation must be confirmed with medical records of the actual procedure.\n       * Information must be captured appropriately within the site's source documents.\n12. Patient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents).\n\nExclusion Criteria:\n\n1. Patient has had ≥ 6 prior lines of chemotherapy. Surgery of the recurrence is allowed.\n2. Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n3. Patient has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy) within 21 days or \\\u003C 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.\n\n   Note: Palliative radiation therapy to a small field ≥ 1 week prior to Day 1 of study treatment may be allowed after discussion with the SPONSOR.\n4. Patient with contraindication to chemotherapy or immune checkpoint inhibitor treatments or anti-angiogenic inhibitor\n5. Patients with uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥100 mmHg) based on an average of ≥ 3 BP readings on ≥ 2 sessions.\n6. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)\n7. Patients with current abdominal\u002Fpelvic fistula\n8. Patient has a concomitant malignancy, or patient has a prior non-gynecological malignancy who has been disease-free for \\\u003C 3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.\n9. Patient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both. Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging \\[using the identical imaging modality for each assessment, either MRI or CT scan\\] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.\n10. Patient has a known history of human immunodeficiency virus (HIV; HIV ½ antibodies). Participants with known human immunodeficiency virus(HIV) are allowed if they meet all of the following criteria:\n\n    * Cluster of differentiation 4(CD4) ≥350\u002FμL and viral load \\\u003C50 copies\u002FmL.\n    * No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months before enrollment.\n    * No history of HIV-associated malignancy for the past 5 years.\n    * Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV started \\>4 weeks before study enrollment.\n11. Patient with presence of hepatitis B surface antigen or a positive hepatitis C antibody test result at screening or within 3 months before first dose of dostarlimab treatment.\n\n    * Participants who are hepatitis B surface antigen positive may be enrolled if their HBV-DNA level is below the institutional lower limit.\n    * Participants with chronic hepatitis B virus (HBV) infection who meet the criteria for anti-HBV therapy may be eligible if the participant is on a suppressive antiviral therapy before initiation of cancer therapy.\n    * Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled only if a confirmatory negative hepatitis C RNA polymerase chain reaction is obtained. Hepatitis C participants may be eligible if they both have completed curative therapy and have a hepatitis C viral load \\\u003C!-- Not Allowed Tag Filtered --\\>\\\u003Cquantifiable limit.\n12. Patient has an active autoimmune disease that required systemic treatment in the past 2 years. Replacement therapy is not considered a form of (eg, thyroid hormone or insulin).\n13. diagnosis immunodeficiency receiving steroid any other immunosuppressive within 7 days prior to first dose study treatment. Patients who have received acute and\\>\u002For low-dose systemic immunosuppressive medications (e.g,, a one-time dose of dexamethasone for nausea or chronic use of ≤ 10 mg\u002Fday of prednisone or dose equivalent corticosteroid) may be enrolled in the study after discussion with and approval by the Sponsor. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) is allowed.\n14. Patient has not recovered (to Grade ≤ 1) from previous anti-cancer therapy-induced adverse events (AEs).\n\n    Note: Patients with Grade ≤ 2 neuropathy, Grade ≤ 2 alopecia, or Grade ≤ 2 fatigue are an exception to this criterion and may qualify for the study.\n15. Patient has not recovered adequately from AEs or complications from any major surgery prior to starting therapy. Major surgical procedures, other than for diagnosis, within 4 weeks prior to initiation of study treatment\n16. Patient has a known hypersensitivity to bevacizumab or dostarlimab components or excipients.\n17. Patient is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.\n18. Patient is considered a poor medical condition due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).\n19. Patients with known history of non-infectious pneumonitis that required steroids or has current pneumonitis.\n20. Use of any of the following immunomodulatory agents within 28 days prior to the first dose of study drug:\n\n    * Interferons\n    * Interleukins\n    * Live vaccine Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster, yellow fever, rabies, BCG, and typhoid vaccine. mRNA and adenoviral-based COVID-19 vaccines are considered non-live and are not exclusionary. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed as other killed vaccines, if done at least 2 weeks prior the first dose of study drug; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n21. Patient who are pregnant or lactating, or plan to become pregnant or lactate during the expected duration of the study, from screening through 180 days after the last dose of study drug.","FEMALE",{"count":345,"type":21},198,[79],"Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +\u002F- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.\n\n198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio.\n\n1. Group A: Dostarlimab monotherapy\n\n   * First 3 cycles: Dostalimab 500mg every 3 weeks, IV\n   * 4 cycles \\~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV\n2. Group B: Dostarlimab + Bevacizumab combination therapy\n\n   * First 3 cycles: Dostalimab 500mg every 3 weeks, IV\n   * 4 cycles \\~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV\n   * Bevacizumab administered IV at 15 mg\u002Fkg every 3 weeks until disease progression or unacceptable toxicity\n3. Group C: General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)",[349,350,351,352,353,354],"Ovarian Neoplasms","Endometrial Neoplasms","Uterine Cervical Neoplasms","Vulvar Cancer","Vagina Neoplasm","Clear Cell Carcinoma","2026-04-30",{"date":328,"type":32},{"date":358,"type":32},"2024-01-22",{"date":143,"type":21},{"name":38,"class":39},27,{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":98,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":373,"conditions":374,"keywords":379,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":40},"100636780","simulation-based-interprofessional-education-for-operating-room-teams-100636780","NCT07570134","Simulation-Based Interprofessional Education for Operating Room Teams","Simulation-Based Interprofessional Education for Surgical Residents: A Prospective Study Design for Team-Based Competency Development","Surgical IPE","Inclusion Criteria:\n\n* Adults aged 19 years or older.\n* Affiliated with Yongin Severance Hospital and meeting one of the following criteria:\n* Postgraduate year 1-2 surgical resident;\n* Newly appointed anesthesia nurse practitioner with less than 6 months of experience in the relevant role;\n* Newly appointed operating room nurse with less than 6 months of operating room experience.\n* Able to participate in the planned study procedures during the study period.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Individuals who do not provide written informed consent.\n* Individuals who are unable to complete the baseline or post-intervention questionnaires.\n* Individuals whose rotation, leave of absence, resignation, transfer, or work schedule change makes participation in the study procedures infeasible.\n* Individuals judged by the investigator to be inappropriate for study participation.",{"count":371,"type":21},30,[24],"This single-center, prospective, single-arm pilot study will evaluate a simulation-based interprofessional education program for early-career operating room team members at Yongin Severance Hospital. Participants will include postgraduate year 1-2 surgical residents, newly appointed anesthesia nurse practitioners, and newly appointed operating room nurses. Participants will complete two simulation-based interprofessional education sessions, each including scenario-based team training and structured debriefing. Teamwork self-efficacy and readiness for interprofessional learning will be assessed before and after the educational intervention. The study will also assess program completion as a feasibility outcome. Optional semi-structured interviews may be conducted to explore participants' perceptions of the program and suggestions for improvement.",[375,376,377,378],"Medical Education","Interprofessional Relations","Patient Safety","Teamwork",[380,381,382,383,384,385,386,387,388],"Interprofessional education","simulation training","operating room","teamwork","surgical education","nursing education","patient safety","readiness for interprofessional learning","RIPLS","2026-04-29",{"date":328,"type":32},{"date":392,"type":21},"2026-05-01",{"date":394,"type":21},"2027-04-25",{"name":38,"class":39},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":405,"studyType":225,"phases":4,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":40},"100573475","registry-study-on-rare-cancers-in-korea-100573475","NCT06746766","Registry Study on Rare Cancers in Korea","rarecancer","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Confirmed rare cancer\n* Life expectancy ≥3 months\n\nExclusion Criteria:\n\n-Serious or unstable medical\u002Fpsychiatric conditions",{"count":404,"type":21},500,"5 Years","This study aims to determine the participation rate of patients with registered rare cancers in clinical research.",[408],"Rare Cancer",[408],"2026-04-27",{"date":355,"type":32},{"date":413,"type":32},"2024-11-18",{"date":415,"type":21},"2027-12-01",{"name":38,"class":39},{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":40},"100408999","phase-2-pemetrexed-cisplatin-with-soft-tissue-sarcoma-100408999","NCT04605770","Pemetrexed, Cisplatin With Soft Tissue Sarcoma","A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Pemetrexed\u002FCisplatin Chemotherapy for Patients With Metastatic\u002FRecurrent Soft Tissue Sarcoma in 4- Independent Histologic Subtypes","ALBATROSS","Inclusion Criteria:\n\n* histologically confirmed, advanced\u002Fmetastatic STS\n* Is ≥ 19 years of age\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1\n* laboratory values indicating adequate organ function\n* a documented postmenopausal woman, or is a premenopausal woman with negative urine or serum pregnancy test\n* life expectancy ≥ 12 weeks\n\nExclusion Criteria:\n\n* previously received more than 2 regimens of cytotoxic chemotherapy\n* received chemotherapy, surgery to major organ, or radiotherapy within the last 2 weeks\n* ongoing toxicity (≥ CTCAE grade 2) from previous anticancer therapy\n* central nervous system (CNS) metastases requiring active treatment\n* diagnosis of second malignancy or has a history of active malignancy within the past 3 years\n* other medical conditions where the study treatment is intolerable\n* history of active infection\n* hypersensitivity to pemetrexed or any of its excipients\n* Co-administration with yellow fever vaccine\n* pregnancy",{"count":426,"type":21},164,[79],"Soft tissue sarcoma (STS) is rare malignancy of mesodermal origin, representing less than 1% of all malignant neoplasms. They are a group of diseases encompassing diverse histological subtypes with very different biomorphologies, prognoses, and responses to treatments. At advanced stages of STS, anticancer treatments are less effective and the prognosis is poor with a median survival of 8 to 18 months. Doxorubicin and ifosfamide given each alone or in their combination have represented the mainstream of anticancer treatments in metastatic STS. However, salvage treatments for patients with progression after doxorubicin\u002Fifosfamide-based treatment are limited and anticancer agents such as gemcitabine\u002Fdocetaxel, pazopanib, eribulin and trabectedin are currently used as a standard of care (SOC).\n\nFor metastatic sarcoma, a study of pemetrexed alone in patients with refractory STS who have progressed after doxorubicin and\u002For ifosfamide-based anticancer treatment was conducted. In this study including 48 patients, most of whom had relatively poor course of disease with disease progression after the 2nd- and\u002For 3rd-line treatment, pemetrexed was well tolerated and associated with 5% of response rate and 33% of 3-month progression-free rates suggesting potential antitumor efficacy with good tolerability profile with refractory STS.\n\nHowever, as conventional agents have showed different efficacy depending on various subtypes of STS, a confirmatory study to see clinical utilities of a given regimen by subtype is required also for pemetrexed\u002Fcisplatin. Therefore, the investigators intend to proceed this phase 2 clinical trial to evaluate the efficacy and safety of pemetrexed\u002Fcisplatin combination therapy in patients with advanced\u002Fmetastatic STS who received up to two-lines of prior palliative anticancer treatments with histological subtype-specific cohorts (leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumor, and others) in order to provide a basis for a subsequent phase 3 study by selecting histological subtype(s) in which the efficacy of study regimen is to be proven.",[430],"Sarcoma,Soft Tissue",{"date":355,"type":32},{"date":433,"type":32},"2020-12-22",{"date":435,"type":21},"2027-11-01",{"name":38,"class":39},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":447,"briefSummary":448,"conditions":449,"keywords":452,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":463,"leadSponsor":464,"locationsCount":4},"100636069","lbbap-vs-cs-pacing-for-crt-in-permanent-atrial-fibrillation-and-heart-failure-sync-af-100636069","NCT07560891","LBBAP vs. CS Pacing for CRT in Permanent Atrial Fibrillation and Heart Failure (SYNC-AF)","Left Bundle Branch Area Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy for Patients With Permanent Atrial Fibrillation and Heart Failure: The SYNC-AF Trial","SYNC-AF","Inclusion Criteria:\n\n1. Age ≥19 years\n2. Indication for CRT (CRT-P or CRT-D) device implantation per current guidelines\n3. Permanent atrial fibrillation (with or without planned AVJ ablation)\n4. Ability to understand the purpose of the study and provide written informed consent\n\nExclusion Criteria:\n\n1. Prosthetic tricuspid valve\n2. Prior myocardial infarction involving the interventricular septal area\n3. Life expectancy less than 12 months\n4. Unable to comply with planned 12-month follow-up for any reason\n5. Pregnancy\n6. History of heart transplantation\n7. Persistent left superior vena cava (PLSVC)",{"count":446,"type":21},44,[24],"This is a prospective, multicenter, randomized controlled trial comparing Left Bundle Branch Area Pacing (LBBAP)-based cardiac resynchronization therapy (CRT) with conventional coronary sinus (CS) lead-based CRT in patients with permanent atrial fibrillation (AF) and heart failure (HF) who meet indications for CRT device implantation.\n\nAtrial fibrillation and heart failure frequently coexist, and both rapid heart rate and its irregularity contribute to worsening cardiac function. Atrioventricular junction (AVJ) ablation combined with CRT (biventricular pacing) has been established as an effective strategy for rate control and cardiac resynchronization in this population, supported by Class I recommendation in the 2021 ESC guidelines. However, conventional biventricular CRT via the CS lead can induce artificial electrical dyssynchrony, particularly in patients with a narrow QRS complex, potentially limiting its benefit.\n\nConduction system pacing (CSP), including LBBAP, has emerged as a physiologic alternative that directly stimulates the native conduction system, preserving synchronous ventricular activation. Recent evidence (ALTERNATIVE-AF trial) suggests CSP may be superior to biventricular CRT in permanent AF patients undergoing AVJ ablation. However, no randomized controlled trial has directly compared LBBAP-based CRT with CS lead-based CRT in this specific population.\n\nThe SYNC-AF trial will randomize 44 patients (22 per arm) to either LBBAP or CS pacing for CRT. The primary endpoint is change in left ventricular ejection fraction (LVEF) at 12 months as assessed by echocardiography in a blinded core laboratory. Secondary endpoints include changes in QRS duration, major adverse clinical events, device\u002Fprocedure-related complications, and ventricular arrhythmia burden.",[450,128,451],"Atrial Fibrillation (AF)","Cardiomyopathies",[453,454,455,456,457,458,459,128],"LBBAP","Left Bundle Branch Area Pacing","CRT","Cardiac Resynchronization Therapy","Permanent Atrial Fibrillation","Conduction System Pacing","AVJ Ablation","2026-04-23",{"date":392,"type":32},{"date":31,"type":21},{"date":143,"type":21},{"name":38,"class":39},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":98,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":22,"phases":474,"briefSummary":475,"conditions":476,"keywords":479,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":40},"100635284","comparison-of-patient-understanding-and-anxiety-according-to-the-delivery-method-of-educational-videos-100635284","NCT07550686","Comparison of Patient Understanding and Anxiety According to the Delivery Method of Educational Videos","Comparison of Patient Understanding and Anxiety According to the Delivery Method of Educational Videos: A Prospective Randomized Study in Radiotherapy Patients","Inclusion Criteria:\n\n* Age ≥ 20 years\n* Patients scheduled for radiotherapy\n* Ability to watch video and comprehend audio, as assessed by the investigator\n* ECOG performance status 0-1\n\nExclusion Criteria:\n\n* Patients unable to complete questionnaires due to cognitive impairment or psychiatric disorders",{"count":473,"type":21},136,[24],"This study aims to evaluate whether a generative artificial intelligence (AI)-based educational video is more effective than a conventional video in improving patient understanding and reducing anxiety before radiation therapy.\n\nIn this prospective, randomized controlled study, participants will be assigned in a 1:1 ratio to either an AI-based avatar video group or a conventional video group consisting of PowerPoint slides with voice narration. Both videos will be standardized to have similar duration (approximately 5 minutes), identical key messages, and the same summary points.\n\nAfter providing informed consent, participants will complete questionnaires before and after watching the assigned video, as well as during the first week of treatment. Outcomes will include anxiety levels, knowledge comprehension, and satisfaction with the educational video.\n\nA total of 136 patients scheduled to undergo radiation therapy will be enrolled from two institutions. The findings of this study are expected to provide evidence on the effectiveness of AI-based educational tools in enhancing patient education and reducing pre-treatment anxiety.",[477,478],"Radiotherapy","Patient Education",[480,478,477],"Educational Video",{"date":389,"type":32},{"date":483,"type":32},"2025-12-01",{"date":485,"type":21},"2027-11-28",{"name":38,"class":39},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":496,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":40},"100629222","phase-4-effect-of-zastaprazan-on-platelet-reactivity-of-clopidogrel-after-percutaneous-coronary-intervention-100629222","NCT07471867","Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention","Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention: A Randomized Double-Blind Pilot Study (EZ-STAR)","EZ-STAR","Inclusion Criteria:\n\n1. Age 19 years or older at the time of providing informed consent.\n2. Patients with Chronic Coronary Syndrome (CCS) who have undergone Percutaneous Coronary Intervention (PCI) and agreed to participate in the study.\n3. Patients who are required to maintain dual antiplatelet therapy (DAPT) including clopidogrel for at least 6 months after PCI.\n4. Patients who have voluntarily provided written informed consent to participate in this clinical study.\n\nExclusion Criteria:\n\n1. History of hypersensitivity to P-CABs, PPIs, benzimidazoles, aspirin, clopidogrel, or any of the excipients in the study drugs.\n2. History of or planned surgery that may affect gastric acid secretion, such as upper gastrointestinal resection, acid suppression surgery, or gastric mucosal resection. (However, patients who have undergone simple perforation repair of the stomach or duodenum, appendectomy, cholecystectomy, hysterectomy, or endoscopic\u002Flaparoscopic resection of benign tumors are eligible).\n3. Diagnosis of Zollinger-Ellison syndrome or inflammatory diseases (e.g., pancreatitis, or inflammatory bowel diseases such as Crohn's disease or ulcerative colitis).\n4. Currently receiving HIV protease inhibitors (atazanavir, nelfinavir) or rilpivirine-containing products.\n5. Abnormal blood chemistry values within 4 weeks prior to screening: AST, ALT, ALP, or total bilirubin \\> 3 times the upper limit of normal (ULN). Estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m², calculated using the IDMS-traceable MDRD equation.\n6. Recent Medication Use: Use of medications expected to affect the study results, such as P2Y12 inhibitors (other than the prescribed clopidogrel), within 2 weeks prior to baseline.\n7. Pregnant or lactating women, or women with a positive pregnancy test.\n8. Patients with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.",{"count":100,"type":21},[299],"The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.",[499],"Chronic Coronary Syndrome",[499,501],"zastaprazan","2026-04-22",{"date":504,"type":32},"2026-04-24",{"date":506,"type":32},"2026-04-02",{"date":508,"type":21},"2028-07-12",{"name":38,"class":39},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":343,"minAge":222,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":527,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":40},"100619095","phase-2-trastzumab-deruxtecan-versus-soc-in-recurrent-ovarian-that-progressed-on-prior-parp-inhibitor-therapy-100619095","NCT07340164","Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","A Phase 2, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan Versus Investigator's Choice Chemotherapy in Recurrent Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy: TROY (APGOT-OV14)","TROY","Inclusion Criteria:\n\n* 1\\. Adults ≥18 years of age on the day of signing the Informed Consent Form. Follow local regulatory requirements if the legal age of consent for trial participation is \\>18 years old.\n\n  2\\. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.\n\n  3\\. Has HER2 expression per 2016 ASCO-CAP gastric cancer IHC scoring (3+\u002F2+\u002F1+) guidelines by local tests.\n\n  4\\. Availability of tumor tissue for translational research: A formalin-fixed paraffin-embedded (FFPE) tumorblock (preferred) or at least 20 slides (unstained, freshly cut, serial sections) must be submitted.\n\n  5\\. Histologically confirmed high grade serous or high grade endometrioid ovarian, primary peritoneal, and\u002For fallopian tube cancer that is recurrent.\n\n  6\\. Patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n  7\\. Radiologically confirmed\u002Fdocumented disease progression while on PARP inhibitor therapy in either first or second-line maintenance setting Note: Documentation of disease progression must be within 180 days of last PARPi dose taken. Surgical salvage intervention and\u002For focal ablative therapies are allowed.\n  1. Clinically benefited from PARPi maintenance prior to documented progression, as defined by at least 6 months of treatment duration with no progressive disease observed.\n  2. Progression on first-line maintenance PARP inhibitor: Participants are allowed maximum 1 additional line of platinum-based chemotherapy before study entry (note: treatment-free interval on platinum rechallenge must be \\> 6 months, with documented disease progression prior to study entry.\n  3. Progression on second-line maintenance PARP inhibitor: Participants are not allowed any additional systemic anticancer treatment before study entry.\n\n     8\\. Patient with measurable disease according RECIST 1.1 criteria. 9. LVEF ≥50% within 28 days before randomization. 10. Patient has adequate organ function, defined as follows:\n\n  a) Absolute neutrophil count ≥ 1,500 cells\u002FμL b) Platelets ≥ 100,000 cells\u002FμL c) Hemoglobin ≥ 9 g\u002FdL or ≥ 5.6 mmol\u002FL d) Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 50mL\u002Fmin using the Cockcroft-Gault equation for patients with creatinine levels \\> 1.5× institutional ULN e) Total bilirubin ≤ 1.5× ULN (≤ 2.0 x ULN in patients with known Gilbert's syndrome) or direct bilirubin ≤ 1× ULN f) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN g) International normalized ratio or prothrombin time (PT) ≤1.5× ULN and activated partial thromboplastin time ≤1.5× ULN. Patients receiving anticoagulant therapy must have a PT or partial thromboplastin within the therapeutic range of intended use of anticoagulants.\n\n  11\\. Patient must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of nonchildbearing potential. Nonchildbearing potential is defined as follows:\n  1. Patient is ≥ 45 years of age and has not had menses for \\> 1 year.\n  2. A follicle-stimulating hormone value in the postmenopausal range upon screening evaluation if amenorrhoeic for \\\u003C 2 years without a hysterectomy and oophorectomy.\n  3. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation:\n* Documented hysterectomy or bilateral oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.\n* Tubal ligation must be confirmed with medical records of the actual procedure.\n* Information must be captured appropriately within the site's source documents. 12. Patient of childbearing potential must agree to use a highly effective method of contraception with their partners starting from time of consent through 150 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient (Information must be captured appropriately within the site's source documents) 13. Has proteinuria \\\u003C2+. If proteinuria is ≥2+, 24-hour urine must demonstrate \\\u003C1 g of protein in 24 hours.\n\nExclusion Criteria:\n\n\\- 1. Primary platinum-refractory disease defined as disease progression during primary platinum-based chemotherapy or platinum-resistant disease defined as disease progression within 6 months of the last platinum administration in the second-line setting.\n\n2\\. History of additional malignancy within 3 years before the date of enrolment. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor, is considered cured with minimal risk of recurrence within 3 years. 3. Patient has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy) within 21 days or \\\u003C 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.\n\nNote: The washout period for radiation therapy is as follows: ≥ 4 weeks for palliative stereotactic radiation to chest and ≥2 weeks palliative stereotactic radiation therapy to other anatomic areas.\n\n4\\. Patient has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.\n\nNote: Patients with previously treated brain metastases may participate provided they are stable (without evidence of disease progression by imaging \\[using the identical imaging modality for each assessment, either MRI or CT scan\\] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability. 5. Active and\u002For uncontrolled infection. The following exceptions apply:\n\n1. Participants with HIV infection are eligible if followings are met: a. CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening, b. Virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) at the time of screening and for at least 12 weeks before screening, c. No AIDS-defining opportunistic infections or conditions within the past 12 months, d. On stable ART regimen, without changes in drugs or dose modification, for at least 4 weeks before trial entry (Day 1) and agree to continue ART throughout the trial.\n2. Participants with evidence of chronic HBV infection are eligible if the followings are met: a. the HBV viral load is \\\u003C2000 IU\u002FmL b. start or maintain antiviral treatment, if clinically indicated as per the investigator. c. they have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST\u002FALT \\\u003C3 × ULN, which are not attributable to HBV infection.\n3. Participants with a history of HCV infection are eligible if History of hepatitis C infection eligible if the HCV viral load is below the level of detection in the absence of antiviral therapy during the previous 4 weeks and if they Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST\u002FALT \\\u003C3 × ULN, which are not attributable to HCV infection.\n\n   6\\. Patient has not recovered (i.e., to Grade ≤ 1 or to baseline) from cytotoxic therapy-induced adverse events(AEs).\n\nNote: Patients with Grade ≤ 2 neuropathy, Grade ≤ 2 alopecia, or Grade ≤ 2 fatigue are an exception to this criterion and may qualify for the study.\n\n7\\. Patient has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.\n\n8\\. Patient has a known hypersensitivity to the active substances or to any excipients of the study intervention 9. Evidence of active or ongoing bowel obstruction 10. Has a history of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required corticosteroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n\n11\\. Uncontrolled or significant cardiovascular disease, including the following:\n\n1. QT interval corrected with Fridericia's formula interval \\>470 ms (average of triplicate determinations).\n2. Diagnosed or suspected long QT syndrome or known family history of long QT syndrome.\n3. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.\n4. Myocardial infarction within 6 months prior to screening.\n5. Uncontrolled angina pectoris within 6 months prior to screening.\n6. New York Heart Association Class 2 to 4 congestive heart failure.\n7. Patients with uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥100 mmHg) based on an average of ≥ 3 BP readings on ≥ 2 sessions.\n8. Complete left or right bundle branch block.\n9. Patients with troponin levels above ULN at screening (as defined by the manufaccturer), and wit any MI related symptoms. (For patients with elevated troponin levels but no MI symptoms, a cardiology consultation during the screening period is recommended..\n\n   12\\. Patient is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.\n\n   13\\. Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) 14. Patients with current abdominal\u002F pelvic fistula. 15. Patient is considered a poor medical condition due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study(including obtaining informed consent).\n\n   16\\. Prior exposure to other HER2-targeted agents or antibody-drug conjugate that consists of an exatecan derivative that is a topoisomerase I inhibitor 17. Patient is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 7 months after the last dose of study treatment, or lactating woman.\n\n   18\\. Live vaccines within 30 days of first dose of study intervention and while receiving study intervention. Administration of inactivated vaccines (i.e. inactivated influenza vaccine) is permitted. Inactivated RNA or nonreplicating viral vector-based SARS-CoV-2 vaccines are allowed, as approved by local\u002Fregional Health Authorities. Novel live attenuated SARS-CoV-2 vaccines are not permitted.",{"count":519,"type":21},116,[79],"Ovarian, fallopian tube, and peritoneal cancers are often diagnosed at an advanced stage, requiring chemotherapy. Recently, the standard treatment, platinum-based chemotherapy plus PARP inhibitors, has extended disease-free survival (PFS). However, most patients eventually develop resistance to PARP inhibitors and become unresponsive to conventional treatments. Therefore, an effective standard treatment for patients who relapse after PARP inhibitor resistance has not yet been established. Meanwhile, HER2 protein expression has been identified in some patients, drawing attention as a new therapeutic target.\n\nTrastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC) targeting HER2, has already demonstrated efficacy and safety in other HER2-positive cancers. This study aimed to explore the potential of T-DXd as a new treatment option by evaluating the efficacy and safety of T-DXd in patients with ovarian, fallopian tube, and peritoneal cancer who relapsed after PARP inhibitor treatment and who express HER2.\n\nParticipants will:\n\n* Arm A: T-DXd +\u002F- Bevacizumab, IV, every 3weeks\n* Arm B: Platinum-based chemotherapy +\u002F- Bevacizumab, IV",[523,524,525,526],"Ovarian Cancer","Ovarian Carcinoma, Recurrent","Ovarian Cancer Metastatic Recurrent","Ovarian Cancer (OvCa)",[516,528,529],"APGOT-OV14","ENGOT-ov92","2026-04-17",{"date":532,"type":32},"2026-04-20",{"date":534,"type":32},"2026-02-26",{"date":536,"type":21},"2030-12-31",{"name":38,"class":39},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":222,"maxAge":153,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":555,"locationsCount":4},"100635046","phase-2-gemcitabine-and-docetaxel-with-or-without-bevacizumab-onbevzi-for-soft-tissue-sarcoma-100635046","NCT07547592","Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma","Phase II, Randomized Trial of Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Previously Treated Soft Tissue Sarcoma","Inclusion Criteria:\n\n1. Histologically confirmed advanced leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), liposarcoma, or angiosarcoma with 1-2 prior chemotherapy\n\n   : neoadjuvnat or adjuvant chemotherapy is counted as one regimen\n2. Age ≥19 years, \\\u003C80 years\n3. ECOG performance status of 0-1\n4. Has at least 1 measurable lesion (as defined by RECIST v1.1).\n5. Has adequate organ function defined by the following criteria:\n\n   * Hb ≥ 9.0 g\u002FdL\n   * Absolute neutrophil count (ANC) ≥ 1500 \u002FµL\n   * Platelet ≥ 75,000\u002F µL\n   * Total Bilirubin: ≤ 1.5 × UNL (upper normal limit) (≤ 2 × UNL in patients with liver metastasis)\n   * Serum Creatinine: ≥ 50 mL\u002Fmin\n   * AST(SGOT)\u002FALT(SGPT): ≤ 3.0 × UNL or ≤ 5.0 × UNL (in patients with liver metastasis)\n   * Alkaline Phosphatase (ALP): ≤ 3.0 × UNL or ≤ 5.0 × UNL (in patients with liver or bone metastasis)\n6. Female patient of childbearing potential has a negative serum or urine pregnancy test for β-hCG\n7. Able to provide written informed consent and comply with the protocol requirements\n\nExclusion Criteria:\n\n1. Patient who has had chemotherapy, radiotherapy, or biological therapy within 2 weeks prior to entering the study\n2. More than 3 prior cytotoxic agents\n3. previously received treatment with bevacizumab, gemcitabine, or docetaxel\n4. Unresolved toxicities from prior anticancer therapy ≥ Grade 2 according to NCI CTCAE, excluding alopecia, vitiligo, and laboratory abnormalities defined in the inclusion criteria\n5. Major surgery within 28 days prior to randomization.\n6. Active or prior documented autoimmune or inflammatory disorders\n7. Unstable cardiovascular disease\n8. Has an active infection requiring parenteral treatment\n9. History of another primary malignancy\n10. Uncontrolled or active CNS metastasis and\u002For carcinomatous meningitis\n11. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study\n12. Pre-existing interstitial lung disease (ILD)",{"count":546,"type":21},92,[79],"Arm1- bevacizumab (Onbevzi) at a dose of 15 mg\u002Fkg administered as a 30-minute intravenous infusion on Day 1 of each 21-day cycle, followed by intravenous infusion of gemcitabine and docetaxel in sequence. On Day 8 of each cycle, gemcitabine and docetaxel will be administered as a 60-minute intravenous infusion.\n\nArm2- On Day 1 of each 21-day cycle, gemcitabine will be administered first, followed by docetaxel as an intravenous infusion. On Day 8, gemcitabine and docetaxel will be administered as intravenous infusions.",[550],"Neoplasms of Connective and Soft Tissue With an Unspecified Anatomical Site","2026-04-16",{"date":460,"type":32},{"date":108,"type":21},{"date":169,"type":21},{"name":38,"class":39},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":563,"maxAge":564,"enrollmentInfo":565,"targetDuration":4,"studyType":22,"phases":567,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":40},"100634843","amyloid-monoclonal-antibody-treatment-in-pd-patients-with-coexistent-ad-pathology-100634843","NCT07544953","Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology","Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease","Inclusion Criteria:\n\n1. Patients diagnosed with Parkinson's disease\n2. Amyloid deposition confirmed by FBB PET\n3. Mild cognitive impairment or early dementia (CDR 0.5 or 1) on neuropsychological tests\n4. Adults aged 50-90 years\n\nExclusion Criteria:\n\n1. Cases in which lecanemab administration is contraindicated (based on recommendations from the Korean Dementia Association)\n2. Cases in which neuropathologies other than Parkinson's disease or Alzheimer's disease are suspected as the underlying disease","50 Years","90 Years",{"count":566,"type":21},60,[24],"This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology. Lecanemab, an anti-amyloid monoclonal antibody, was apporoved by the US FDA in July 2023 and in South Korea in May 2024, as a disease-modifying therapy based on its clinical efficacy and reduction of amyloid plaques in patients with early-stage Alzheimer's disease (AD). AD pathology is also common in PD, and approximately 35% of patients with PD dementia have co-existing AD pathology. Currently, no mediations have been developed to slow the progression of PD. Therefore, this study aimed to determine whether reducing the amyloid burden in patients with PD with co-exsistent AD pathology could potentially slow disease progression. To test it, patients with PD with mild cognitive impairment or early dementia, who were confirmed to have amyloid deposition through amyloid imaging, would be enrolled as a treatment arm, and the degree of reduction of amyloid plaque after 18 months of lecanemab administration would be investigated.",[570],"Parkinson Disease",[572,573,574],"Parkinson disease","amyloid","lecanemab","2026-04-15",{"date":502,"type":32},{"date":578,"type":21},"2026-05",{"date":580,"type":21},"2030-11",{"name":38,"class":39},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":588,"enrollmentInfo":589,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":602},"100633375","an-open-label-prospective-study-to-evaluate-the-efficacy-and-safety-of-pegfilgrastim-in-triple-negative-breast-cancer-patients-receiving-ac-regimen-following-paclitaxel-and-carboplatin-as-neoadjuvant-therapy-100633375","NCT07525869","An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy","Inclusion Criteria:\n\n* 1\\. Women diagnosed with triple-negative breast cancer by pathology or cytology. 2. Age ≥19 and ≤70 years. 3. ECOG performance status 0-1. 4. Stage II-III breast cancer confirmed pathologically or clinically. 5. Planned to receive AC chemotherapy following paclitaxel\u002Fcarboplatin as neoadjuvant therapy.\n\n  6\\. Adequate organ function:\n  1. Absolute neutrophil count (ANC) ≥1,000 cells\u002Fmm³\n  2. Platelet count ≥75,000 cells\u002Fmm³\n  3. Creatinine clearance ≥50 mL\u002Fmin or serum creatinine \\\u003C1.5× ULN\n  4. Total bilirubin ≤1.5× ULN\n  5. AST ≤2.5× ULN\n  6. ALT ≤2.5× ULN 7. Ability to provide written informed consent and willingness to comply with study procedures.\n\n     Exclusion Criteria:\n* 1\\. Prior treatment with cytotoxic chemotherapy. 2. Prior treatment with G-CSF or pegylated G-CSF. 3. History of conditions that may affect bone marrow function (e.g., severe liver or kidney disease).\n\n  4\\. Receipt of radiotherapy within 4 weeks prior to study initiation. 5. Active uncontrolled infection or inflammatory disease that may affect study outcomes.\n\n  6\\. Receipt of blood transfusion within 60 days prior to study initiation. 7. Pregnant, breastfeeding, or unwilling to use appropriate contraception. 8. Any condition judged by the investigator to make the patient unsuitable for participation.","70 Years",{"count":590,"type":21},40,[24],"This open-label, prospective, single-arm clinical study aims to evaluate the efficacy and safety of pegfilgrastim in preventing febrile neutropenia (FN) among patients with triple-negative breast cancer (TNBC) receiving anthracycline\u002Fcyclophosphamide (AC) chemotherapy following neoadjuvant paclitaxel\u002Fcarboplatin therapy. In the Keynote-522 regimen, paclitaxel and carboplatin are administered prior to the AC phase, which may increase cumulative myelosuppression and subsequently elevate the risk of FN during AC. Despite this clinical concern, real-world evidence supporting the prophylactic use of pegfilgrastim in Korean patients undergoing this regimen remains insufficient.\n\nA total of 40 adult TNBC patients will be enrolled. Pegfilgrastim 6 mg will be administered subcutaneously once per cycle on Day 2 of each AC cycle (Cycles 1-4), approximately 24 hours after chemotherapy completion. The primary objective is to assess the incidence of FN during the four AC cycles. Secondary objectives include hospitalization due to FN, incidence of Grade 4 neutropenia, delays or dose reductions in chemotherapy due to neutropenia, and evaluation of hematologic and non-hematologic toxicities.\n\nThis study is descriptive in nature and does not involve hypothesis-testing sample size calculations. The sample size of 40 was determined based on feasible drug supply and is expected to provide clinically meaningful insight when compared with existing real-world data, in which the FN risk during AC without prophylactic G-CSF is historically reported at approximately 20-25%. The findings from this study may offer essential clinical evidence supporting the preventive use of pegfilgrastim during the AC phase in TNBC patients treated with the paclitaxel\u002Fcarboplatin-leading neoadjuvant regimen.",[594],"Triple-Negative Breast Cancer","2026-04-14",{"date":532,"type":32},{"date":598,"type":32},"2025-10-28",{"date":600,"type":21},"2026-10-27",{"name":38,"class":39},2,{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":319,"enrollmentInfo":609,"targetDuration":4,"studyType":225,"phases":4,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":616,"leadSponsor":618,"locationsCount":4},"100626179","a-prospective-controlled-single-center-confirmatory-study-to-evaluate-the-accuracy-and-safety-of-core-temperature-measurement-using-the-xst600-electronic-thermometer-compared-to-the-3m-spoton-thermometer-in-adult-patients-100626179","NCT07432269","A Prospective, Controlled, Single-Center Confirmatory Study to Evaluate the Accuracy and Safety of Core Temperature Measurement Using the XST600 Electronic Thermometer Compared to the 3M SpotOn Thermometer in Adult Patients","Inclusion Criteria:\n\n1. Males and females aged 19 to 80 years.\n2. Patients requiring continuous temperature monitoring in the Operating Room or Intensive Care Unit.\n3. Subjects (or their legal representatives) who have been fully informed about the study and have voluntarily provided written informed consent.\n\nExclusion Criteria:\n\n1. Skin Conditions: Presence or high risk of skin diseases, wounds, infections, or allergic reactions (e.g., rash) at the application site (forehead).\n2. Medication Interference: \\* Current use of drugs that may interfere with clinical trial results, such as barbiturates (sedatives\u002Fhypnotics), thyroid preparations, or antipsychotic drugs (per ISO 80601-2-56).\n\n   o Administration of antipyretics within the last 120 minutes or immunization within the last month (per ISO 80601-2-56).\n3. Medical History: Any underlying medical condition that may significantly impact the interpretation of the clinical results.\n4. Investigator Discretion: Any individual deemed inappropriate for participation by the principal investigator.",{"count":610,"type":21},117,"The body temperature measured by the skin is easily affected by the measurement environment such as temperature or humidity, and in some cases, the difference from the central body temperature is particularly large. Therefore, there has been an attempt to develop a new method of measuring skin body temperature to predict the central body temperature by measuring body temperature in the skin. The purpose of this study is to evaluate the effectiveness and safety of the core temperature measured using this medical device by comparing the accuracy of the body temperature measured through the XST600 electronic thermometer applying the HF technology developed by Chois Technology with the body temperature measured by the Gold Standard 3M Bair Hugger Temperature Monitoring System Model 370. - Number of target subjects: 117 in total - Basis for calculation: This clinical trial is an corroborating clinical trial to confirm the clinical accuracy and effectiveness of the test equipment (XST600), so it is set based on the requirements of ISO 80601-2-56 (the \"Medical Device Standard\" 50. Electronic thermometer). 1. Total number of target subjects: 117 (105 + 10%) \\* At least 105 participants are required in accordance with ISO 80601-2-56:2017, and 117 participants are targeted by applying the normal research dropout rate of 10%. \\* If the research procedure is completed in 105 participants without dropping out, the study is terminated. ① Normal body temperature subject: 82 (73 participants + 10%): Those with a core temperature of 36.1℃ (10) or more and 38.0℃ or less when measured by RCT. \\* If the research procedure is completed in 73 participants without dropping out, the study is terminated. ② Number of subjects with heating: 35 (32 participants + 10%): Subjects with a core temperature of 38.0℃ or higher when measured by RCT \\* According to ISO 80601-2-56, the maximum number of subjects with heating is 32, by applying the standard that should not exceed 30%, and the target is 35, by applying the normal research dropout rate of 10%. \\* If the research procedure is completed without dropping out of only 32 subjects, the study is terminated.",[613],"All Patients Who Require Monitoring of Their Temperatures Over the Age of 19",{"date":532,"type":32},{"date":208,"type":21},{"date":617,"type":21},"2027-01-15",{"name":38,"class":39},""]